ASTH (Astrana Health) 3-Year RORE % : -26.79% (As of Mar. 2026)


ASTH Astrana Health Inc ASTH
87 GF Score
Price $44.43
GF Value $82.34
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Astrana Health 3-Year RORE %?

Astrana Health ASTH +2.37% 87 3-Year RORE % is -26.79 as of Mar. 2026. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.34 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Astrana Health ranks worse than 72.82% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Astrana Health's 3-Year RORE % for the quarter that ended in Mar. 2026 was -26.79%.

The industry rank for Astrana Health's 3-Year RORE % or its related term are showing as below:

ASTH's 3-Year RORE % is ranked worse than
72.82% of 607 companies
in the Healthcare Providers & Services industry
Industry Median: 0.74 vs ASTH: -26.79

Astrana Health  (NAS:ASTH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Astrana Health 3-Year RORE % Related Terms


Astrana Health 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Astrana Health's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astrana Health 3-Year RORE % Chart

Astrana Health Annual Data
Trend Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.34 -0.55 -8.44 -3.46 -31.44

Astrana Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.61 -16.61 -31.71 -31.44 -26.79

ASTH vs MD, SGRY, ADUS: 3-Year RORE % Comparison

For the Medical Care Facilities subindustry, Astrana Health's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astrana Health 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Astrana Health's 3-Year RORE % falls into.


ASTH
87GF Score
Astrana Health Inc ASTH
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astrana Health 3-Year RORE % Calculation

Astrana Health's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.61-1.32 )/( 2.65-0 )
=-0.71/2.65
=-26.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -26.79 mean?
Astrana Health (ASTH) has a 3-Year RORE % of -26.79 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Astrana Health and its competitors. According to the industry distribution chart, Astrana Health ranks #442 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 72.8%.
Is Astrana Health's 3-Year RORE % too high?
Astrana Health's current 3-Year RORE % is -26.79. Based on the distribution chart, Astrana Health ranks #442 out of 607 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's 3-Year RORE % compare to MD and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #442 out of 607 companies for 3-Year RORE %. This places Astrana Health in the lower half of its industry. The industry median 3-Year RORE % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current 3-Year RORE % is -26.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.34, compared to a current price of $44.43 — trading 46% below its estimated fair value. The current 3-Year RORE % is -26.79. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Astrana Health (ASTH), the current 3-Year RORE % is -26.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astrana Health (ASTH) Overvalued in 2026?

Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued. The current stock price of $44.43 is trading 46% below its estimated GF Value™ of $82.34. GuruFocus considers Astrana Health to be Significantly Undervalued.

Key valuation signals for ASTH:

  • 3-Year RORE %: -26.79
  • GF Value™: $82.34 vs. price of $44.43 (46% below fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astrana Health Business Description

Other Exchanges 3AM:Germany
Address 1668 South Garfield Avenue, 2nd Floor, Alhambra, CA, USA, 91801
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score

Get the complete analysis for ASTH

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.43
Price
$82.34
GF Value